“copyright’s hazard profile is minimal sufficient to justify further explorations in clinical trial configurations. Having said that, this only applies to cautiously built research contexts with screened adult subjects, and won't apply to some other use of copyright.”1 Offered promising scientific-demo effects, quite a few stakeholders are